Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·Why does MSI-high matter more in some colorectal cancer stages?
Review or Meta-AnalysisA 2021 meta-analysis linked high microsatellite instability with less spread overall; survival differences were clearest in stages II and III.
-
Evidence date ·Why is holding adenoid cystic carcinoma steady easier than making it respond?
Review or Meta-AnalysisA 2021 review describes mostly stable disease across adenoid cystic carcinoma treatments and points to weak immune recognition as a barrier to checkpoint drugs.
-
Evidence date ·After CAR-T remission, could a stem cell transplant help it last?
Review or Meta-AnalysisA 2021 review of 18 studies linked stem cell transplant after CAR-T to fewer relapses and better survival, but found no clear overall-survival benefit in two subgroups.
-
Evidence date ·Who was the afatinib study about, and what counted as a response?
Clinical TrialPhysicians' charts and tumor measurements offer two ways to count response in this afatinib study. Its broad title and lung cancer listing leave the patient mix unclear.
-
Evidence date ·What lets some tumor-fighting T cells sustain a response?
Review or Meta-AnalysisCheckpoint drugs rely in part on a lasting supply of tumor-fighting T cells. A 2021 review explains why cell state and tumor access matter.
-
Evidence date ·What can a tumor response tell someone with advanced cancer of the upper urinary tract?
Review or Meta-AnalysisA 2021 review found a 21.2% tumor response rate with immunotherapy in upper urinary tract cancer; it did not establish a survival benefit over platinum chemotherapy.
-
Evidence date ·How a mouse model tracked melanoma after T cells lost control
Peer-Reviewed PaperPatient-derived T cells slowed engineered melanoma tumors in mice, but growth resumed. Repeating the transfer or blocking PD-1 improved later control.
-
Evidence date ·Can releasing T-cell brakes help when COVID-19 inflames the lungs?
Review or Meta-AnalysisA February 2021 review asks whether cancer drugs that block PD-1 could restore antiviral T-cell activity in severe COVID-19, and examines lung risks and trial plans.
-
Evidence date ·Treatment paths after immunotherapy for advanced urothelial cancer
Review or Meta-AnalysisA 2021 review found that 25%–35.5% of patients in two studies received another treatment after immunotherapy stopped; treatment paths varied widely.
-
Evidence date ·Why the two-drug melanoma comparison matters beyond older treatments
Review or Meta-AnalysisA 2021 review reports survival gains for nivolumab over chemotherapy and ipilimumab, while leaving open whether adding ipilimumab improves survival further.